Optimizing First-Line Systemic Therapy Selection in Advanced Hepatocellular Carcinoma (HCC): A Biomarker Approach Using Circulating Cell-Free DNA (cfdna) (atezolizumab Plus Bevacizumab Vs. Lenvatinib Vs. Sorafenib)
CANCER RESEARCH（2024）
Key words
Intratumor Heterogeneity
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined